稀有植物和动物遗传信息驱动制药利润,在联合国生物多样性会议COP16之前引起生物盗版问题。 Rare plant and animal genetic information drives pharmaceutical profits, raising biopiracy concerns ahead of UN biodiversity conference COP16.

最近一篇文章强调稀有植物和动物的遗传信息在推动制药和生物技术行业的利润方面的潜力,引起人们对所有权和补偿的道德关切。 A recent article highlights the potential of genetic information from rare plants and animals to drive profits in pharmaceutical and biotech industries, raising ethical concerns about ownership and compensation. 随着快速的DNA测序使现有协定复杂化,生物盗版问题出现,公司获利,而来源国却得不到补偿。 As rapid DNA sequencing complicates existing agreements, the issue of biopiracy emerges, with companies profiting without compensating source countries. 即将举行的联合国生物多样性会议(COP16)旨在为保护生物多样性的人,特别是土著社区建立公平的赔偿机制。 The upcoming UN biodiversity conference, COP16, aims to establish fair compensation mechanisms for those conserving biodiversity, particularly Indigenous communities.